Article
Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.
Canadian journal of gastroenterology & hepatology - 1 Jan 2014
Cooper Curtis, Shafran Stephan, Greenbloom Susan, Enns Robert, Farley John, Hilzenrat Nir, Williams Kurt, Elkashab Magdy, Abadir Nabil, Neuman Manuela
Abstract excerpt
BACKGROUND: Serum tumour necrosis factor-alpha (TNF-α) levels correlate negatively with hepatitis C virus (HCV) antiviral response. OBJECTIVES: To test the hypothesis that a single infliximab induction dose would positively influence on-treatment virological response and sustained virological response (SVR). METHODS: The present study was a phase IIIB, randomized, prospective, open-label pilot trial conducted at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.